Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-viral agent

An antiviral agent, hepatitis virus technology, applied in the direction of antiviral agent, antitumor drug, digestive system, etc., can solve problems such as no specific proof

Inactive Publication Date: 2008-03-26
MITSUBISHI TANABE PHARMA CORP
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, as to whether HGF itself has the function of directly eliminating hepatitis virus, there is no concrete proof so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-viral agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] (Example 1) Effect of HGF Addition in HCV-Replicon Cells Relative to Inhibition of HCV-Replicon Replication of IFN

[0073] (Experimental materials and methods)

[0074] As a cell line for replicating HCV in vitro, a clone of HCV-replicon cells, #5-15 (purchased from ReBLikon GmbH), was used using the human hepatoma cell line Huh7 as a mother line. Suspend #5-15 in Dulbecco's Eagle's (Dalbetsukoi-イ-グル) MEM medium containing 2% bovine fetal serum, dilute at 1.5×10 4 / 100μl / well (well) was seeded on a 96-well plate. As a blank, a well (Day 0 ) in which cells were not seeded and only a medium was added was set. at 5% CO 2 After culturing in a humid incubator at 37°C for one day and night under gas, 50 μl of human recombinant IFNα (manufactured by BIOMEDICAL LABORATORIES, Cat. No. 11105-1, lot No. #2122) and / or human Recombinant HGF (manufactured by our company, Lot. 920629). The final concentration of IFNα is 0, 0.1, 0.3 international unit (IU) / ml, the final concentra...

Embodiment 2

[0081] (Example 2) Effects of IFN, HGF or combinations thereof on the proliferation of HCV-replicon cell lines

[0082] (Experimental materials and methods)

[0083] In order to investigate whether the decrease in the replication amount of HCV-replicon confirmed in Example 1 was due to the decrease in the number of cells itself, the following experiment was performed.

[0084] Suspend #5-15 in Dalubetsu Koi-Gru MEM medium containing 2% bovine fetal serum, and use 1.5×10 4 / 100μl / well seeded on a 96-well plate. As a blank, a well (Day 0 ) in which cells were not seeded and only a medium was added was set. at 5% CO 2 After culturing in a humid incubator at 37°C for one day and night under gas, 50 μl of human recombinant IFNα (manufactured by BIOMEDICAL LABORATORIES, Cat. No. 11105-1, lot No. #2122) and / or human Recombinant HGF (manufactured by our company, Lot. 920629). The final concentration of IFNα was 0, 0.1, 0.3 international unit (IU) / ml, the final concentration of HG...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An antiviral agent consisting of hepatocyte growth factor (HGF) or an agonist of the HGF receptor, and a medicament for prophylactic and / or therapeutic treatment of a disease caused by hepatitis C virus comprising using said agent simultaneously or separately with other anti-viral agent.

Description

technical field [0001] The present invention relates to an antiviral agent. Background technique [0002] Hepatitis virus type C (Hepatitis virus type C, hereinafter referred to as "HCV") is becoming the leading cause of hepatitis, liver cirrhosis, and liver cancer in Japan. It is estimated that there are about 1.5 million patients with chronic hepatitis and about 300,000 patients with liver cirrhosis in Japan, 70%-80% of which are caused by HCV. HCV is infected through blood, so the infection caused by blood transfusion can be almost ruled out by screening the blood transfused. Become a breeding ground for new patients with chronic hepatitis. [0003] Since HCV only infects humans and chimpanzees, and there is no suitable infective or reproducing strain in vitro, the development of drugs for hepatitis C has been slow. Various medicines have been used in the treatment, but so far only various interferon (hereinafter abbreviated as "IFN") preparations and ribavirin are eff...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61K31/7056A61K38/21A61K45/00A61K45/06A61P31/14A61P43/00
CPCA61K38/1833A61K38/212A61K31/7056A61K45/06A61P1/16A61P31/12A61P31/14A61P35/00A61P43/00A61K2300/00
Inventor 石井健久伊丹清马
Owner MITSUBISHI TANABE PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com